Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Ezra Cohen, MD, FRCPC, FASCO, of the University of California, San Diego, CA, speaks about a recent clinical trial (NCT02101034) that examined the effect of palbociclib/cetuximab combination therapy in metastatic platinum-refractory head and neck cancer. The results were very positive, showing an additive and perhaps even synergistic effect from the two therapies. Dr Cohen discusses the data and touches upon the upcoming data from the Phase III stage of this trial.
Positive results for palbociclib/cetuximab therapy in head and neck cancer
